Company / Revenue
Arbutus Biopharma Corp Revenue History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Revenue
$14.1M
FY2025
5-year range
$6.2M / $39.0M
FY2021-FY2025
Trend
+128.2%
vs FY2024
Sector context
#134 of 155
Health Care
What the data says
Arbutus Biopharma Corp's revenue of $14M is lower than 86% of companies in the Health Care sector (FY2025). Revenue returned to growth in FY2025 after 2 years of decline, reaching $14M.
Based on SEC 10-K filings.
$14M in FY2025 with a 5-year CAGR of +18.6%.
Declined from $18M to $14M over the past 2 years.
Health Care sector context is included.
Revenue over time
Growth rates
- 3-Year CAGR
- -28.8%
- 5-Year CAGR
- +18.6%
- 10-Year CAGR
- -
Sector benchmark
Bottom 14% in Health CareTop 86% of 155This company $14.1M Sector average $4.5B
▼
-99.7% below sector average
Key checks
Key Insights
- 5-year CAGR of +18.6%, indicating consistent growth.
- In FY2025, revenue increased 128.2% year-over-year.
- Ranks #134 out of 155 companies in the Health Care sector.
- Peak revenue was recorded in FY2022.
Company context
Key Data Points
- Altman Z-Score -11.01 (distress zone, below 1.8 threshold)
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | RevenueValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $14.1M | +128.2% |
| FY2024 | $6.2M | -66.0% |
| FY2023 | $18.1M | -53.5% |
| FY2022 | $39.0M | +255.1% |
| FY2021 | $11.0M | +82.8% |
| FY2020 | $6.0M | +278.8% |
| FY2019 | $1.6M | -85.2% |
| FY2018 | $10.7M | +0.0% |
| FY2017 | $10.7M | +617.6% |
| FY2016 | $1.5M | -93.6% |
As of FY2025 · SEC 10-K · Updated Jul 2, 2026